Inositol Anxiety Meta-analysis: What the Evidence Says

Quick Answer

Inositol Anxiety Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Whatever the underlying causes, AnxDs are transdiagnostically associated with chronically or recurrently elevated anxiety and arousal with attendant neurobiological adaptations that may themselves have pathogenic consequences. [Maddock Richard J. (2025); evidence level 1]
• However, such reports have generally not been confirmed at the meta-analytic level with the exception of reduced levels in Alzheimer's disease and autism. [Maddock Richard J. (2025); evidence level 1]
• Besides diabetes, metformin has found off-label applications, most notably in PCOS and weight management, but also in other areas as cardiovascular diseases, oncology, and neurological disorders. [Russo Michele (2025); evidence level 4]
• Metformin appears to have a synergistic relationship with a healthy gut microbiota environment, as coadministration of metformin with probiotics improved metabolic function in patients with T2DM. [Russo Michele (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For inositol anxiety meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Maddock Richard J. (2025). Transdiagnostic reduction in cortical choline-containing compounds in anxiety disorders: a 1 H-magnetic resonance spectroscopy meta-analysis. DOI: 10.1038/s41380-025-03206-7. PMCID: PMC12602319. PMID: 40913113. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12602319/
• Russo Michele (2025). Metformin and Myo-Inositol: A Comparative Analysis. DOI: 10.1159/000549646. PMCID: PMC12721718. PMID: 41269915. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12721718/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.